Blocking the progression of prostate cancer to a more aggressive form
Official title: Targeting drivers of tumor heterogeneity to block the progression to neuroendocrine prostate cancer
Funded at Weill Medical Coll of Cornell Univ · NIH-10662642 · Data updated 2026-11-12
This study is looking at how certain features of prostate cancer can turn it into a more aggressive type called neuroendocrine prostate cancer, using special techniques to understand the genes involved, and it hopes to find new ways to treat or prevent this tougher form of cancer that could help patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $196,745 |
| NIH project number | 1K22CA269707-01A1 |
| Project ID | NIH-10662642 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced prostate cancer who are experiencing treatment resistance.
✕Less likely to help
Patients with early-stage prostate cancer or those who do not have advanced disease may not benefit from this research.
What this research studies
This research investigates how certain tumor characteristics in prostate cancer can lead to a more aggressive form known as neuroendocrine prostate cancer (NEPC). By using advanced genetic techniques, including CRISPR, the study aims to identify and modify specific genes that contribute to this transition. The research utilizes a unique mouse model and organoid technology to closely mimic human prostate cancer, allowing for a better understanding of how these tumors develop and respond to treatments. Patients may benefit from insights gained about potential new therapies that could prevent or treat NEPC.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that prevent the progression of prostate cancer to its more aggressive neuroendocrine form.
How similar studies have gone: Other research has shown promise in targeting tumor heterogeneity in various cancers, suggesting that this approach may yield significant insights.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Brady, Nicholas James — Weill Medical Coll of Cornell Univ
- Study coordinator: Brady, Nicholas James
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.